Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C MOSES

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Diabetes, Obesity & Metabolism|September 30, 2020
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
The American Journal of Medicine|November 3, 2007
Biological variability of transferrin saturation and unsaturated iron-binding capacityPaul C Adams, David M Reboussin, Richard D Press, et al.
Diabetes, Obesity & Metabolism|April 7, 2020
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|February 23, 2019
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)Richard E Pratley, Scott S Emerson, Edward Franek, et al.
Pancreas|October 3, 2014
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER TrialWilliam M Steinberg, Michael A Nauck, Bernard Zinman, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 28, 2006
Mixture models of serum iron measures in population screening for hemochromatosis and iron overloadChristine E McLaren, Kuo-Tung Li, Gordon D McLaren, et al.
Current Biology : CB|November 8, 2024
Ancient DNA challenges prevailing interpretations of the Pompeii plaster castsElena Pilli, Stefania Vai, Victoria C Moses, et al.
American Heart Journal|November 2, 2013
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trialSteven P Marso, Neil R Poulter, Steven E Nissen, et al.
Clinical Chemistry|April 19, 2005
Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) studyPaul C Adams, David M Reboussin, Cathie Leiendecker-Foster, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Diabetes, Obesity & Metabolism|September 30, 2020
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
The American Journal of Medicine|November 3, 2007
Biological variability of transferrin saturation and unsaturated iron-binding capacityPaul C Adams, David M Reboussin, Richard D Press, et al.
Diabetes, Obesity & Metabolism|April 7, 2020
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTESimon Heller, Ildiko Lingvay, Steven P Marso, et al.
Diabetes, Obesity & Metabolism|February 23, 2019
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)Richard E Pratley, Scott S Emerson, Edward Franek, et al.
Pancreas|October 3, 2014
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER TrialWilliam M Steinberg, Michael A Nauck, Bernard Zinman, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 28, 2006
Mixture models of serum iron measures in population screening for hemochromatosis and iron overloadChristine E McLaren, Kuo-Tung Li, Gordon D McLaren, et al.
Current Biology : CB|November 8, 2024
Ancient DNA challenges prevailing interpretations of the Pompeii plaster castsElena Pilli, Stefania Vai, Victoria C Moses, et al.
American Heart Journal|November 2, 2013
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trialSteven P Marso, Neil R Poulter, Steven E Nissen, et al.
Clinical Chemistry|April 19, 2005
Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) studyPaul C Adams, David M Reboussin, Cathie Leiendecker-Foster, et al.
Pageof 21